Skye Bioscience, Inc. (SKYE)
Skye Bioscience, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $0.55, up 1.66% on the session, giving a market capitalisation of $19.3M. On trailing twelve-month figures it carries a trailing P/E of -0.38, a net margin of 0.0%. Its beta of 2.99 implies it has historically moved more than the broad market.
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Skye Bioscience, Inc. is most often compared with the following Healthcare names: